Uholanzi -
Kiholanzi -
CBG-MEB (College ter Beoordeling van Geneesmiddelen)
transiderm-nitro 15, pleister voor transdermaal gebruik 15 mg/24 uur
novartis pharma b.v. haaksbergweg 16 1101 bx amsterdam - nitroglycerine - pleister voor transdermaal gebruik - bruine inkt ; copolymeer van ethyleen-vinylacetaat (9 pct. vinylacetaat) ; dimeticon (e 900) ; lactose 1-water ; polyethyleenterephthalaat-ethylvinylacetaat film ; polyvinylchloride ; siliciumdioxide (e 551) ; siliconen kleefstof bio-psa qcf7-4354, dimeticon (e 900) ; lactose 1-water ; medical adhesive ch 15, hotmelt (ri) ; siliciumdioxide (e 551), - glyceryl trinitrate
Uholanzi -
Kiholanzi -
CBG-MEB (College ter Beoordeling van Geneesmiddelen)
transiderm-nitro 5 mg/24 uur, pleister voor transdermaal gebruik
medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - nitroglycerine 25 mg/stuk - pleister voor transdermaal gebruik - bruine inkt ; copolymeer van ethyleen-vinylacetaat (9 pct. vinylacetaat) ; dimeticon (e 900) ; lactose 1-water ; polyethyleenterephthalaat-ethylvinylacetaat film ; polyvinylchloride ; siliciumdioxide (e 551), - glyceryl trinitrate
Uholanzi -
Kiholanzi -
CBG-MEB (College ter Beoordeling van Geneesmiddelen)
transiderm-nitro 5, pleister voor transdermaal gebruik 5 mg/24 uur
novartis pharma b.v. haaksbergweg 16 1101 bx amsterdam - nitroglycerine 25 mg/stuk - pleister voor transdermaal gebruik - bruine inkt ; copolymeer van ethyleen-vinylacetaat (9 pct. vinylacetaat) ; dimeticon (e 900) ; lactose 1-water ; polyethyleenterephthalaat-ethylvinylacetaat film ; polyvinylchloride ; siliciumdioxide (e 551) ; siliconen kleefstof bio-psa qcf7-4354, bruine inkt ; copolymeer van ethyleen-vinylacetaat (9 pct. vinylacetaat) ; dimeticon (e 900) ; lactose 1-water ; polyethyleenterephthalaat-ethylvinylacetaat film ; polyvinylchloride ; siliciumdioxide (e 551), - glyceryl trinitrate
Uholanzi -
Kiholanzi -
CBG-MEB (College ter Beoordeling van Geneesmiddelen)
butrans® 10 microgram/uur, pleister voor transdermaal gebruik
medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - buprenorfine 10 mg/stuk - pleister voor transdermaal gebruik - blauwe inkt ; copolymeer van 2-ethylhexylacrylaat (75,0), butylacrylaat (15,0), acrylzuur (5,0), vinylacetaat (5,0) ; copolymeer van 2-ethylhexylacrylaat (75,0), butylacrylaat (15,0), acrylzuur (5,0), vinylacetaat (5,0) met aluminiumacetylacetonaat als crosslinkingagent ; levulinezuur ; oleyloleaat ; polyethyleenterephthalaat ; polyethyleenterephthalaat, gesiliconeerd en bekleed met aluminium ; povidon k 90 (e 1201)
Uholanzi -
Kiholanzi -
CBG-MEB (College ter Beoordeling van Geneesmiddelen)
butrans® 20 microgram/uur, pleister voor transdermaal gebruik
medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - buprenorfine 20 mg/stuk - pleister voor transdermaal gebruik - blauwe inkt ; copolymeer van 2-ethylhexylacrylaat (75,0), butylacrylaat (15,0), acrylzuur (5,0), vinylacetaat (5,0) met aluminiumacetylacetonaat als crosslinkingagent ; levulinezuur ; oleyloleaat ; polyethyleenterephthalaat ; polyethyleenterephthalaat, gesiliconeerd en bekleed met aluminium ; povidon k 90 (e 1201)
Uholanzi -
Kiholanzi -
CBG-MEB (College ter Beoordeling van Geneesmiddelen)
butrans® 5 microgram/uur, pleister voor transdermaal gebruik
medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - buprenorfine 5 mg/stuk - pleister voor transdermaal gebruik - blauwe inkt ; copolymeer van 2-ethylhexylacrylaat (75,0), butylacrylaat (15,0), acrylzuur (5,0), vinylacetaat (5,0) ; copolymeer van 2-ethylhexylacrylaat (75,0), butylacrylaat (15,0), acrylzuur (5,0), vinylacetaat (5,0) met aluminiumacetylacetonaat als crosslinkingagent ; levulinezuur ; oleyloleaat ; polyethyleenterephthalaat ; polyethyleenterephthalaat, gesiliconeerd en bekleed met aluminium ; povidon k 90 (e 1201)
Umoja wa Ulaya -
Kiholanzi -
EMA (European Medicines Agency)
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.
